<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02329860</url>
  </required_header>
  <id_info>
    <org_study_id>APTN-III-HCC</org_study_id>
    <nct_id>NCT02329860</nct_id>
  </id_info>
  <brief_title>Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study (AHELP) of Apatinib in Patients With Hepatocellular Carcinoma After Systemic Therapy（Chemotherapy and/or Targeted Therapy）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NanJing PLA 81 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a multicenter, randomized, double-blind, phase III trial. This clinical study&#xD;
      evaluates the efficacy and safety of Apatinib in patients with advanced liver cancer who have&#xD;
      progressed on Systemic Therapy (Chemotherapy and/or Targeted Therapy).&#xD;
&#xD;
      Approximately 400 patients who meet the entry criteria will be randomly assigned in a 2:1&#xD;
      ratio to Apatinib or placebo (1/3 chance to receive placebo).&#xD;
&#xD;
      Primary endpoint of the study is overall survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 13, 2014</start_date>
  <completion_date type="Actual">February 29, 2020</completion_date>
  <primary_completion_date type="Actual">December 15, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Approximately 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression（TTP）</measure>
    <time_frame>Approximately 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Approximately 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response</measure>
    <time_frame>Approximately 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control RATE</measure>
    <time_frame>Approximately 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>750 mg orally (p.o.) every day (qd), 28 days as one cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>orally (p.o.) every day (qd), 28 days as one cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <arm_group_label>Apatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥ 18 years old.&#xD;
&#xD;
          2. Conform to the clinical diagnosis standard strictly or histological or cytological&#xD;
             confirmation of HCC (hepatocellular carcinoma) who cannot benefit from treatments of&#xD;
             established efficacy with higher priority such as resection, local ablation,and with&#xD;
             at least one uni-dimensional measurable lesion by computed tomography (CT) scan or&#xD;
             magnetic resonance imaging (MRI) according to RECIST 1.1.&#xD;
&#xD;
          3. Failure or intolerance to prior treatment with chemotherapy and/or targeted therapy&#xD;
             (Failure is defined as documented radiological progression according to the radiology&#xD;
             charter. Intolerance is defined as ≥ grade 4 hematologic toxicities, ≥ grade 3&#xD;
             non-hematologic toxicities ≥ grade 2 heart, liver or kidney damage).&#xD;
&#xD;
          4. Systemic therapy must have been completed ≥2 weeks before randomization (AEs due to&#xD;
             prior treatment ≤ grade 1).&#xD;
&#xD;
          5. Liver function status Child-Pugh Class A or B (score≤7).&#xD;
&#xD;
          6. Barcelona Clinic Liver Cancer stage Category B or C.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group Performance Status of 0 or 1 within 1 week before&#xD;
             randomization.&#xD;
&#xD;
          8. Life expectancy of at least 12 weeks.&#xD;
&#xD;
          9. HBV DNA ≤ 2000IU/ml or 1×10E+4 copy/ml.&#xD;
&#xD;
         10. Adequate bone marrow, liver and renal function as assessed by the following laboratory&#xD;
             tests conducted within 1 week before randomization.&#xD;
&#xD;
             HB ≥ 90g/L; ANC≥1.5×10E+9/L; PLT≥80×10E+9/L; ALB ≥ 29g/L; ALT and AST &lt; 5×ULN; TBIL&#xD;
             ≤1.5×ULN; Cr ≤1.5×ULN&#xD;
&#xD;
         11. Women of childbearing potential and men must agree to use adequate contraception .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any local treatment (included but not limited: resection, radiotherapy, TAE, TACE,&#xD;
             TAI, RFA or PEI) within 4 weeks of randomization.&#xD;
&#xD;
          2. Known hepatic duct carcinoma, mixed cell carcinoma or fibrolamellar hepatocellular&#xD;
             carcinoma, known history or suffering from other cancer(except of cured skin basal&#xD;
             cell carcinoma or carcinoma in situ of cervix).&#xD;
&#xD;
          3. Patients who will receive liver transplantation.&#xD;
&#xD;
          4. Ascites with clinical symptoms, i.e. require Abdominal paracentesis or drainage&#xD;
             treatment such as or Child-Pugh Score&gt;2.&#xD;
&#xD;
          5. Hypertension and unable to be controlled within normal level following treatment of&#xD;
             anti-hypertension agents (systolic blood pressure &gt; 140 mmHg, diastolic blood pressure&#xD;
             &gt; 90 mmHg).&#xD;
&#xD;
          6. Suffered from grade II or above myocardial ischemia or myocardial infarction,&#xD;
             uncontrolled arrhythmias (including QT interval male ≥ 450 ms, female≥ 470 ms).&#xD;
&#xD;
          7. Grade III-IV cardiac insufficiency, according to NYHA criteria or echocardiography&#xD;
             check: LVEF&lt;50%.&#xD;
&#xD;
          8. Factors to affect oral administration（such as Patients unable to swallow oral&#xD;
             medications, chronic diarrhea and ileus etc. situations evidently affect drug oral&#xD;
             medication and absorption）.&#xD;
&#xD;
          9. Previous digestive tract bleeding history within 6 months or evident gastrointestinal&#xD;
             bleeding tendency, such as,：Esophageal varices with bleeding risk, local active&#xD;
             ulcerative lesions, fecal occult blood≥（++）；if fecal occult blood（+），gastroscope check&#xD;
             is required.&#xD;
&#xD;
         10. The Within 28 days ahead of randomization, experience abdomen fistula,&#xD;
             gastrointestinal perforation, or abdominal abscess&#xD;
&#xD;
         11. Coagulation abnormalities (INR &gt; 1.5 x ULN, or PT &gt; ULN +4 seconds), with bleeding&#xD;
             tendency or are receiving thrombolytic or anticoagulant therapy;&#xD;
&#xD;
         12. Occurrence of central nervous system metastatic or known brain metastatic;&#xD;
&#xD;
         13. Objective evidence of previous or current pulmonary fibrosis history, interstitial&#xD;
             pneumonia, Pneumoconiosis, radiation pneumonitis, drug-related pneumonia, Pulmonary&#xD;
             function damaged seriously etc.&#xD;
&#xD;
         14. Proteinuria ≥ (++) or 24 hours total urine protein &gt; 1.0 g.&#xD;
&#xD;
         15. Received powerful inhibitor of CYP3A4 within 7 days or powerful inducer of CYP3A4&#xD;
             within 12 days before randomization.&#xD;
&#xD;
         16. Pregnant or breast-feeding women; patients with fertility will not or there is no way&#xD;
             to adopt effective contraceptive measures.&#xD;
&#xD;
         17. Mental disorders history, or Psychotropic drug abuse history.&#xD;
&#xD;
         18. Patients who has bone metastasis, has received Palliative radiotherapy (radiotherapy&#xD;
             area &gt; 5% marrow area).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jiangsu hengrui medicine CO. LTD</name>
      <address>
        <city>Lianyungang</city>
        <state>Jiangsu</state>
        <zip>222047</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>December 30, 2014</study_first_submitted>
  <study_first_submitted_qc>December 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2015</study_first_posted>
  <last_update_submitted>January 31, 2021</last_update_submitted>
  <last_update_submitted_qc>January 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

